An Oxford-based ovarian cancer specialist has published a paper outlining a new classification which categorises different subtypes of cells and determines which ones can lead to more severe cancer outcomes. This approach, dubbed the ‘Oxford Classification of Carcinoma of the Ovary’ or ‘Oxford Classic’ for short, was developed by Professor Ahmed Ahmed, who is supported … Read more
Ancient gene mutation found to cause rare hereditary condition
UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN). In a paper, published in the journal Brain, geneticists and clinicians from the University of Oxford and University College London who led the international study said they had found that the novel disease gene VWA1 … Read more
Oxford study confirms medium-term impact of COVID-19
A study looking at the longer-term impact of COVID-19 has found that a significant proportion of COVID-19 patients discharged from hospital reported symptoms of breathlessness, fatigue and depression and had limited exercise capacity several weeks after leaving hospital. The University of Oxford scientists carrying out the C-MORE study found that at two to three month … Read more
Paper urges use of genomics in care of monogenic IBD
Gastroenterology experts have had a position paper published that calls for genomic technologies to be considered an integral part of patient care to investigate patients at risk for monogenic forms of inflammatory bowel disease (IBD). The authors include a number of NIHR Oxford BRC-supported researchers. The paper, published in the Journal of Paediatric Gastroenterology and … Read more
Oxford COVID-19 vaccinations begin
The NHS has launched the roll-out of the new Oxford AstraZeneca coronavirus vaccine, with patients at Oxford University Hospitals NHS Foundation Trust (OUH) the very first to get the life-saving jab. Among the first to be vaccinated was Prof Andrew Pollard, the Oxford BRC investigator who has played a key role in developing the vaccine. … Read more
IBD treatments do not increase susceptibility to COVID-19, study finds
Research by Oxford scientists has shown that rates of COVID-19 infection are not increased in patients with inflammatory bowel disease (IBD) who are being treated with the drugs infliximab or vedolizumab. The study data suggest there is no reason for treatment with these drugs to be stopped. The paper, published on the pre-print server medRxiv, … Read more
Trial finds no benefit from azithromycin in hospitalised COVID-19 patients
The RECOVERY Trial, the world’s largest randomised trial of potential COVID-19 treatments, has found no convincing evidence that that the widely used antibiotic azithromycin has any meaningful clinical benefits for patients who have been hospitalised with COVID-19. Azithromycin was regarded a promising treatment as it is an antibiotic that also reduces inflammation, a key feature … Read more
AI test rules out a COVID-19 diagnosis within one hour in A&E
An artificial intelligence test has been shown to be able to rapidly screen patients arriving in emergency departments for COVID-19, using clinical information routinely available within the first hour of coming to hospital. Results of the CURIAL study, published in The Lancet Digital Health, show that the AI test correctly predicted the COVID-19 status of … Read more
Key step for hepatitis research as patient database created
For the first time, a comprehensive database comprising an initial cohort of more than 1,300 patients with chronic hepatitis B or hepatitis C infections has been developed for potential future research into the conditions. The methodology to develop a pipeline to collect and manage this data has been presented in a paper published in BMJ … Read more
Peer-reviewed results of phase 3 Oxford coronavirus vaccine trial demonstrate efficacy
The vaccine against SARS-CoV-2 developed by researchers from the University of Oxford and AstraZeneca is safe and effective according to the peer-reviewed findings of the phase 3 trial. The pooled analysis of the trial across two different dose regimens resulted in an average efficacy of 70.4%; however, one dosing regimen achieved 90% efficacy. The new study, … Read more
- 1
- 2
- 3
- …
- 57
- Next Page »